Analyst Maintains Hold on Bristol-Myers Squibb, Keeps Price Target Unchanged at $61 Amid Pipeline Uncertainty

Analyst Asad Haider from Goldman Sachs maintained a Hold rating on Bristol-Myers Squibb and keeping the price target at $61.00.

Asad Haider has given his Hold rating due to a combination of factors tied to Bristol-Myers Squibb’s current execution and future uncertainties. The latest quarter largely matched expectations, and management now sees performance trending toward the upper end of 2026 guidance, helped in part by stronger-than-anticipated contribution from Eliquis, yet this upside is mainly from a mature asset rather than new growth drivers.

At the same time, the company’s long-term outlook is heavily dependent on several late-stage pipeline catalysts, including milvexian, Cobenfy, and admilparant, with pivotal data largely concentrated toward year-end. Until these readouts clarify the durability and scale of future revenue streams, Haider expects the stock to trade in a relatively tight range around current levels, so he maintains a neutral stance with an unchanged $61 price target.

In another report released today, BMO Capital also maintained a Hold rating on the stock with a $60.00 price target.